Beyond FEV1 in COPD: A review of patient-reported outcomes and their measurement

International Journal of COPD

Volumn 7, Issue , 2012, Pages 697-709

  Jones, Paul ^a   Miravitlles, Marc ^b   van der Molen, Thys ^c   Kulich, Karoly ^d  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Dyspnea; Exacerbations; Health related quality of life; Patient reported outcomes; Questionnaire development

Indexed keywords

CAPACITY OF DAILY LIVING DURING THE MORNING QUESTIONNAIRE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY QUESTIONNAIRE; CLINICAL COPD QUESTIONNAIRE; CLINICAL TRIAL (TOPIC); COPD ASSESSMENT TEST; COUGHING; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; DYSPNEA 12; DYSPNEA MANAGEMENT QUESTIONNAIRE COMPUTER ADAPTIVE TEST; EVIDENCE BASED MEDICINE; EXACERBATIONS OF CHRONIC PULMONARY DISEASE TOOL; FATIGUE; FORCED EXPIRATORY VOLUME; GLOBAL CHEST SYMPTOMS QUESTIONNAIRE; HEALTH STATUS; HUMAN; LIVING WITH COPD QUESTIONNAIRE; LONDON CHEST ACTIVITY OF DAILY LIVING QUESTIONNAIRE; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SELF REPORT; SHORTNESS OF BREATH WITH DAILY ACTIVITIES QUESTIONNAIRE; SLEEP DISORDER; SPIROMETRY; ST GEORGE RESPIRATORY QUESTIONNAIRE; VALIDATION PROCESS; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE; COST OF ILLNESS; DISEASE COURSE; LUNG; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PSYCHOLOGICAL ASPECT; SEVERITY OF ILLNESS INDEX;

ACTIVITIES OF DAILY LIVING; COST OF ILLNESS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LUNG; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SELF REPORT; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84872228384     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S32675     Document Type: Review

References (108)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2010. Available from: http://www.goldcopd.com. Accessed July 16, 2012.
2. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(4): 822-832.
3. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880-887.
4. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med. 2007;101(1):146-153.
5. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
6. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347-360.
7. Jones PW. Issues concerning health-related quality of life in COPD. Chest. 1995;107(Suppl 5):187S-193S.
8. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr. 2000;71(5):1033-1047.
9. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD phar-macological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-468.
10. Dorman PJ, Waddell F, Slattery J, Dennis M, Sandercock P. Are proxy assessments of health status after stroke with the EuroQol questionnaire feasible, accurate, and unbiased? Stroke. 1997;28(10): 1883-1887.
11. Low G, Gutman G. Couples' ratings of chronic obstructive pulmonary disease patients' quality of life. Clin Nurs Res. 2003;12(1): 28-48.
12. Santiveri C, Espinalt M, Diaz Carrasco FX, Marín A, Miguel E, Jones PW. Evaluation of male COPD patients' health status by proxies. Respir Med. 2007;101(3):439-445.
13. Guidance for Industry. Patient-reported Outcome Measures: Use in Medical Product Delvelopment to Support Labelling Claims. US Department of Health and Human Services, Food and Drug Admin-istration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH); 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInforma-tion/Guidances/UCM193282.pdf. Accessed July 16, 2012.
14. Draft Guidance for Industry. Qualification Process for Drug Devel-opment Tools. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2010. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf. Accessed July 16, 2012.
15. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011;183(3): 323-329.
16. proactivecopd.com [homepage on the Internet]. PROactive website. 2011. Available from: http://www.proactivecopd.com. Accessed July 16, 2012.
17. Troosters T, Brindicci C. PROactive COPD, towards a patient reported outcome capturing physical activity in COPD, 2009. Available from: http://www.ers-education.org/pages/default.aspx?id=1652&idBrowse=57382&det=1. Accessed July 16, 2012.
18. Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010;36(1):96-104.
19. Wilcox TK, Chen WH, Howard KA, et al. Reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in COPD. Am J Respir Crit Care Med. 2010;181:A5429.
20. Yorke J, Russell AM, Swigris J, et al. Assessment of dyspnea in asthma: validation of the Dyspnea-12. J Asthma. 2011;48(6):602-608.
21. Rasch G. Probabilistic Models for Some Intelligence and Attain-ment Tests. Copenhagen, Denmark: Danish Institute for Educational Research; 1960.
22. Hagquist C, Bruce M, Gustavsson JP. Using the Rasch model in nurs-ing research: an introduction and illustrative example. Int J Nurs Stud. 2009;46(3):380-393.
23. Vidotto G, Bertolotti G, Carone M, et al. A new questionnaire specifically designed for patients affected by chronic obstructive pulmonary disease; the Italian Health Status Questionnaire. Respir Med. 2006;100(5):862-870.
24. Jones PW, Kaplan RM. Methodological issues in evaluating measures of health as outcomes for COPD. Eur Respir J Suppl. 2003;41: 13s-18s.
25. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Forgel M. Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med. 2007;101(3):453-460.
26. Mazur W, Kupiainen H, Pitkäniemi J, et al. Comparison between the disease-specific Airways Questionnaire 20 and the generic 15D instruments in COPD. Health Qual Life Outcomes. 2011;9:4.
27. Braido F, Baiardini I, Menoni S, et al. Disability in COPD and its relationship to clinical and patient-reported outcomes. Curr Med Res Opin. 2011;27(5):981-986.
28. Fletcher CM. Standardized questionnaire on respiratory symptoms: a statement prepared and approved by the MRC committee on the aetiology of chronic bronchitis. Br Med J. 1960;2:1665.
29. Burdon JG, Juniper EF, Killian KJ, Hargreaves FE, Campbell EJ. The perception of breathlessness in asthma. Am Rev Respir Dis. 1982;126(5): 825-828.
30. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measure-ment of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-758.
31. Gross NJ. Chronic obstructive pulmonary disease outcome measurements: what's important? What's useful? Proc Am Thorac Soc. 2005;2(4):267-271.
32. Ozalevli S, Ucan ES. The comparison of different dyspnoea scales in patients with COPD. J Eval Clin Pract. 2006;12(5):532-538.
33. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD. 2004;1(2):165-172.
34. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered comput-erized versions of the baseline and transition dyspnea indexes. Chest. 2007;132(4):1283-1290.
35. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest. 2002;121(3):688-696.
36. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Koplan RM. Valida-tion of a new dyspnea measure: the UCSD Shortness of Breath Ques-tionnaire. University of California, San Diego. Chest. 1998;113(3): 619-624.
37. Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax. 2001;56(12):954-959.
38. Jones PW. Assessment of disability. In: Barnes PJ, Drazen JM, Rennard SI, Thomson NC, editors. Asthma and COPD: Basic Mechanisms and Clini-cal Management. San Diego, CA: Elsevier Science Ltd; 2002.
39. Norweg A, Ni P, Garshick E, O'Connor G, Wilke K, Jette AM. A mul-tidimensional computer adaptive test approach to dyspnea assessment. Arch Phys Med Rehabil. 2011;92(10):1561-1569.
40. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010;65(1):21-26.
41. Yorke J, Swigris J, Russell AM, et al. Dyspnea-12 is a valid and reli-able measure of breathlessness in patients with interstitial lung disease. Chest. 2011;139(1):159-164.
42. Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med. 2008;121(9): 789-796.
43. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstruc-tive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9): 972-977.
44. Follick MJ, Ahern DK, Laser-Wolston N. Evaluation of a daily activity diary for chronic pain patients. Pain. 1984;19(4):373-382.
45. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis. 1978;31(12):741-755.
46. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J. 2006;27(5):1040-1055.
47. Kocks JW, Asijee GM, Tsiligianni IG, Kerstjens HA, van der Molen T. Functional status measurement in COPD: a review of available methods and their feasibility in primary care. Prim Care Respir J. 2011;20(3): 269-275.
48. Leidy NK. Subjective measurement of activity in chronic obstructive pulmonary disease. COPD. 2007;4(3):243-249.
49. Stull DE, Leidy NK, Jones PW, Stohl E. Measuring functional performance in patients with COPD: a discussion of patient-reported outcome measures. Curr Med Res Opin. 2007;23(11):2655-2665.
50. Garrod R, Bestall JC, Paul EA, Wedzicka JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med. 2000;94(6):589-596.
51. Miravitlles M, Ferrer M, Pont A, et al. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease: a 2-year follow up study. Thorax. 2004;59(5):387-395.
52. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-1422.
53. Miravitlles M. Prevention of exacerbations of COPD with pharmacotherapy. Eur Respir Rev. 2010;19(116):119-126.
54. Jones RC, Hyland ME, Hanney K, Erwin J. A qualitative study of compliance with medication and lifestyle modification in chronic obstructive pulmonary disease (COPD). Prim Care Respir J. 2004; 13(3):149-154.
55. Jordan N, Lee TA, Valenstein M, Pirraglia PA, Weiss KB. Effect of depression care on outcomes in COPD patients with depression. Chest. 2009;135(3):626-632.
56. de Voogd JN, Wempe JB, Koeter GH, et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest. 2009; 135(3):619-625.
57. Jones P, Higenbottam T. Quantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantification. Proc Am Thorac Soc. 2007;4(8): 597-601.
58. Jones PW, Chen WH, Wilcox TK, Sethi S, Leidy NK; EXACT-PRO Study Group. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest. 2011;139(6):1388-1394.
59. Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010;13(8):965-975.
60. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622-629.
61. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6):1321-1327.
62. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med. 1997;127(12):1072-1079.
63. Gupta B, Kant S. Health related quality of life (HRQOL) in COPD. Internet J Pulmon Med. 2009;11:1.
64. Quirk FH, Jones PW. Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors. Clin Sci. 1990;79(1):17-21.
65. Quirk FH, Baveystock CM, Wilson RC, Jones PW. Influence of demo-graphic and disease related factors on the degree of distress associated with symptoms and restrictions on daily living due to asthma in six countries. Eur Respir J. 1991;4(2):167-171.
66. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and flu-ticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
67. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
68. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
69. Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St George Respiratory Questionnaire. Chest. 2007;132(2):456-463.
70. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
71. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(8):741-750.
72. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42(10):773-778.
73. Schünemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic Respiratory Disease Questionnaire (CRQ). COPD. 2005(1);2: 81-89.
74. Morgan MD. Experience of using the CRQ (Chronic Respiratory Questionnaire). Respir Med. 1991;85 Suppl B:23-24.
75. Meng NH, Chen FN, Lo SF, Cheng WE. Reliability and validity of the Taiwan (Mandarin Chinese) version of the chronic respiratory questionnaire. Qual Life Res. 2011;20(10):1745-1751.
76. Moreira GL, Pitta F, Ramos D, et al. Portuguese-language version of the Chronic Respiratory Questionnaire: a validity and reproducibility study. J Bras Pneumol. 2009;35(8):737-744.
77. Puhan MA, Behnke M, Frey M, et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes. 2004;2(7):1.
78. Vigil L, Guell MR, Morante F, et al. The validity and sensitivity to change of the Spanish self-administered version of the Chronic Respi-ratory Questionnaire (CRQ-SAS). Arch Bronconeumol. 2011;47(3): 343-349. Spanish.
79. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(5):648-654.
80. Dodd JW, Hogg L, Nolan J, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax. 2011;66(1):425-429.
81. Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD Assessment Test (CAT) in a cross-sectional European study. Eur Respir J. 2011;38(1):29-35.
82. Jones PW, Harding G, Wiklund I, et al. Tests of the responsiveness of the chronic obstructive pulmonary disease (COPD) Assessment Test TM (CAT) following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142:134-140.
83. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1:13.
84. McKenna S, Meads D, Doward L, et al. Development and validation of the living with chronic obstructive pulmonary disease questionnaire. Qual Life Res. 2011;20(7):1043-1052.
85. Stucki A, Stucki G, Cieza A, Schuurmans MM, Kostanjsek N, Ruof J. Content comparison of health-related quality of life instruments for COPD. Respir Med. 2007;101(6):1113-1122.
86. Vernon M, Kline Leidy N, Nacson A, Nelsen L. Measuring cough severity: development and pilot testing of a new seven-item cough severity patient-reported outcome measure. Ther Adv Respir Dis. 2010;4(4):199-208.
87. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-343.
88. Yousaf N, Lee KK, Jayaraman B, Pavord ID, Birring SS. The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). Cough. 2011;7(1):4.
89. Reishtein JL. Relationship between symptoms and functional perfor-mance in COPD. Res Nurs Health. 2005;28(1):39-47.
90. Kinsman RA, Yaroush RA, Fernandez E, Dirks JF, Schocket M, Fukuhara J. Symptoms and experiences in chronic bronchitis and emphysema. Chest. 1983;83(5):755-761.
91. Shackell BS, Jones RC, Harding G, Pearse S, Campbell J. "Am I going to see the next morning?"A qualitative study of patients' perspectives of sleep in COPD. Prim Care Respir J. 2007;16(6): 378-383.
92. Owens RL, Malhotra A. Sleep-disordered breathing and COPD: the overlap syndrome. Respir Care. 2010;55(10):1333-1344.
93. Karachaliou F, Kostikas K, Pastaka C, Bagiatis V, Gourgoulianis KI. Prevalence of sleep-related symptoms in a primary care population - their relation to asthma and COPD. Prim Care Respir J. 2007;16(4): 222-228.
94. Peters JB, Heijdra YF, Daudey L, et al. Course of normal and abnormal fatigue in patients with chronic obstructive pulmonary disease, and its relationship with domains of health status. Patient Educ Couns. 2011;85(2):281-285.
95. Mollaoglu M, Fertelli TK, Tuncay FO. Fatigue and disability in elderly patients with chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr. 2011;53(2):e93-e98.
96. Al-shair K, Kolsum U, Berry P, et al. Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. Thorax. 2009;64(11):950-955.
97. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2011;183(3):323-329.
98. Reilly MC, Bracco A, Ricci JF, Santoro J, Stevens T. The validity and accuracy of the Work Productivity and Activity Impairment ques-tionnaire - irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther. 2004;20(4):459-467.
99. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford). 2010;49(4):812-819.
100. Wahlqvist P, Carlsson J, Stalhammar NO, Wiklund I. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD) - results from a cross-sectional study. Value Health. 2002;5(2):106-113.
101. Ståhl E, Jansson SA, Jonsson AC, Svensson K, Lundbäck B, Andersson F. Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD. Health Qual Life Outcomes. 2003;1:18.
102. Fletcher MJ, Upton J, Taylor-Fishwick J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011;11:612.
103. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48(12):1204-1213.
104. Victorson DE, Anton S, Hamilton A, Yount S, Cella D. A conceptual model of the experience of dyspnea and functional limitations in chronic obstructive pulmonary disease. Value Health. 2009;12(6): 1018-1025.
105. Evensen AE. Management of COPD exacerbations. Am Fam Physician. 2010;81(5):607-613.
106. Daudey L, Peters JB, Molema J, et al. Health status in COPD cannot be measured by the St George's Respiratory Questionnaire alone: an evaluation of the underlying concepts of this questionnaire. Respir Res. 2010;11:98.
107. Andenaes R, Moum T, Kalfoss MH, Wahl AK. Changes in health status, psychological distress, and quality of life in COPD patients after hospitalization. Qual Life Res. 2006;15(2):249-257.
108. Testa MA, Simonson DC. Current concepts: assessment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835-840.